LIVN | LivaNova PLC Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	48.34 - 49.06
52 Week Range	42.75 - 64.48
Beta	1.07
Implied Volatility	31.89%
IV Rank	13.55%
Day's Volume	196,967
Average Volume	692,767
Shares Outstanding	54,298,000
Market Cap	2,648,656,440
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2015-10-19

Valuation
Profitability
Growth
Health
P/E Ratio	-157.35
Forward P/E Ratio	N/A
EPS	-0.31
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2,900
Country	UK
Website	LIVN

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN's peers: AHCO, APYX, ATEC, AVNS, AXDX, AXGN, AXNX, MODD, BRKR, XTNT, CLPT, SMLR, CNMD, CTKB, CTSO, CUTR, CVRX, ELMD, DCTH, ESTA, FNA, GKOS, GMED, HYPR, IRMD, IRTC, ITGR, KIDS, LUNG, SIBN, NPCE, OFIX, HSKA, NUVA, LUCD, MASI, MOVE, NVCR, NVNO, NVRO, PEN, PRCT, PROF, QDEL, RPID, SILK, SNN, SRDX, STE, TCMD, TMCI, NXL, CATX

*Chart delayed

Analyzing fundamentals for LIVN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see LIVN Fundamentals page.

Watching at LIVN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on LIVN Technicals page.